Project Details
Description
GLIOCARE: Glioma Imaging Omitting Contrast through Artificial intelligence and Risk Evaluation
The GLIOCARE project investigates if brain tumor magnetic resonance imaging (MRI) can be performed without the injection of gadolinium-based contrast agents whilst maintaining diagnostic accuracy without delay. To reach this goal we rely on three pillars: artificial intelligence, advanced MRI techniques and the exploration of human assessment power without post-contrast sequences. Our fourth pillar is the construction of a large glioma imaging database for continued AI-research. Since brain tumor imaging is currently fully dependent on gadolinium contrast, which is invasive, costly and potentially harmful for health and environment, our project will show valuable directions towards overcoming this dependency. Future patients shall receive diagnostically superior imaging, despite being less invasive.
Amsterdam UMC, locatie VUmc, is the main site of investigation with cooperation partners in the Netherlands and abroad.
The GLIOCARE project investigates if brain tumor magnetic resonance imaging (MRI) can be performed without the injection of gadolinium-based contrast agents whilst maintaining diagnostic accuracy without delay. To reach this goal we rely on three pillars: artificial intelligence, advanced MRI techniques and the exploration of human assessment power without post-contrast sequences. Our fourth pillar is the construction of a large glioma imaging database for continued AI-research. Since brain tumor imaging is currently fully dependent on gadolinium contrast, which is invasive, costly and potentially harmful for health and environment, our project will show valuable directions towards overcoming this dependency. Future patients shall receive diagnostically superior imaging, despite being less invasive.
Amsterdam UMC, locatie VUmc, is the main site of investigation with cooperation partners in the Netherlands and abroad.
Layman's description
We try to find new ways to diagnose brain tumors without the use of contrast agent.
| Status | Active |
|---|---|
| Effective start/end date | 01/04/2022 → … |